Oral semaglutide 14 mg significantly lowered blood sugar (HbA1c down 1.0 percentage point) and body weight (down 3.7 kg) versus placebo over 26 weeks in type 2 diabetes patients with moderate kidney impairment.
-1.0 percentage point HbA1c reductionOral semaglutide 14 mg lowered HbA1c by a full percentage point in patients with type 2 diabetes and moderate kidney impairment over 26 weeks
What the researchers found
At 26 weeks, oral semaglutide 14 mg reduced HbA1c by 1.0 percentage point versus 0.2 for placebo (treatment difference: -0.8 percentage points; p<0.0001). Body weight decreased by 3.7 kg with semaglutide versus 1.1 kg with placebo (treatment difference: -2.7 kg; p<0.0001).
In the on-treatment analysis (excluding patients who discontinued or needed rescue medication), the HbA1c reduction was even larger: -1.1 versus -0.1 percentage points. Completion rates were 82% for semaglutide and 88% for placebo. More patients discontinued semaglutide due to adverse events (15% vs 5%), primarily gastrointestinal symptoms. Renal safety was consistent with the GLP-1 receptor agonist class.
Why it matters
Kidney impairment is extremely common in type 2 diabetes and narrows treatment options because many drugs are cleared through the kidneys. This trial established that oral semaglutide works effectively and safely in this vulnerable population, giving clinicians a new oral option where previously they might have had to rely on insulin or fewer alternatives. It was a key step in the PIONEER program that led to oral semaglutide's broad approval.
The numbers in context
n=324; HbA1c ETD: -0.8 percentage points (p<0.0001); weight ETD: -2.7 kg (p<0.0001); 82% semaglutide completion; 15% discontinuation due to AEs
How the study worked
Randomized, double-blind, placebo-controlled phase 3a trial at 88 sites across 8 countries. Patients with type 2 diabetes and moderate renal impairment (eGFR 30-59) on stable background medication were assigned 1:1 to oral semaglutide (escalated to 14 mg daily) or placebo for 26 weeks. Primary endpoint was change in HbA1c; confirmatory secondary endpoint was change in body weight. Two estimands were used: treatment policy and trial product.
Who was studied
Adults with type 2 diabetes and moderate renal impairment (eGFR 30-59 mL/min/1.73 m²), mean age 70, 52% female, on stable background diabetes medication
What this study cannot tell us
26-week duration only; no long-term renal or cardiovascular outcomes. Novo Nordisk funded. 15% semaglutide discontinuation rate due to adverse events. Moderate renal impairment only (eGFR 30-59). Elderly population (mean age 70).
How to read the evidence
This is a randomized, double-blind, placebo-controlled phase 3a trial published in The Lancet Diabetes & Endocrinology with 324 participants across 88 sites in 8 countries. The rigorous design, adequate sample size, and clear statistical significance place it at the strong evidence level.
When this study was published
Published in 2019, this PIONEER 5 trial data directly supported regulatory approvals for oral semaglutide. The findings remain fully relevant as oral semaglutide (Rybelsus) is now widely prescribed.
The bigger picture
PIONEER 5 is one trial in the larger PIONEER program that tested oral semaglutide across different patient populations and comparators. By demonstrating efficacy in kidney-impaired patients specifically, it filled an important gap — showing that the first oral GLP-1 agonist could serve patients who face the most restricted treatment landscapes. This contributed to the broader transformation of diabetes care by making GLP-1 therapy accessible without injections.
Questions still open
- Does oral semaglutide slow the progression of kidney disease in diabetes patients over the long term?
- Would patients with severe renal impairment (eGFR below 30) tolerate and benefit from oral semaglutide?
- How does the 15% adverse-event discontinuation rate affect real-world treatment adherence?
Common questions
Can people with kidney problems take oral semaglutide?
How much weight did patients lose on oral semaglutide in this trial?
Read the original research
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
The lancet. Diabetes & endocrinology, 7(7), 515-527
Citation
Mosenzon, Ofri; Blicher, Thalia Marie; Rosenlund, Signe; Eriksson, Jan W; Heller, Simon; Hels, Ole Holm; Pratley, Richard; Sathyapalan, Thozhukat; Desouza, Cyrus. (2019). Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.. The lancet. Diabetes & endocrinology, 7(7), 515-527. https://doi.org/10.1016/S2213-8587(19)30192-5